322 related articles for article (PubMed ID: 23424288)
1. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.
McGettigan P; Henry D
PLoS Med; 2013; 10(2):e1001388. PubMed ID: 23424288
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk of NSAIDs: time to translate knowledge into practice.
Reddy KS; Roy A
PLoS Med; 2013; 10(2):e1001389. PubMed ID: 23424289
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
McGettigan P; Henry D
PLoS Med; 2011 Sep; 8(9):e1001098. PubMed ID: 21980265
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
6. Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000-2016: A Drug Utilization Study.
Kristensen KB; Karlstad Ø; Martikainen JE; Pottegård A; Wastesson JW; Zoega H; Schmidt M
Pharmacotherapy; 2019 Feb; 39(2):150-160. PubMed ID: 30636337
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
11. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study.
Kasciuškevičiūtė S; Gumbrevičius G; Vendzelytė A; Ščiupokas A; Petrikonis K; Kaduševičius E
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344261
[No Abstract] [Full Text] [Related]
12. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.
Trelle S; Reichenbach S; Wandel S; Hildebrand P; Tschannen B; Villiger PM; Egger M; Jüni P
BMJ; 2011 Jan; 342():c7086. PubMed ID: 21224324
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
15. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
[TBL] [Abstract][Full Text] [Related]
17. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
Martín Arias LH; Martín González A; Sanz Fadrique R; Vazquez ES
J Clin Pharmacol; 2019 Jan; 59(1):55-73. PubMed ID: 30204233
[TBL] [Abstract][Full Text] [Related]
20. The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka District, Serbia.
Calasan J; Mijatović V; Horvat O; Varga J; Sabo A; Stilinović N
Int J Clin Pharm; 2011 Apr; 33(2):246-51. PubMed ID: 21744192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
